BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC
Launched by CHONNAM NATIONAL UNIVERSITY HOSPITAL · Nov 18, 2010
Trial Information
Current as of June 17, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Stage IIIB/IV or Relapsed NSCLC
- • Age \>= 18 years
- • At least one measurable lesion by RECIST (version 1.1)
- • ECOG PS 0, 1, 2
- • Hematologic profile
- • Hgb \> 8 g/dL, ANC \>= 2,000/m3, Platelet \>= 100,000/m3
- • Hepatic profile
- • Total bilirubin \<= 1.5 x upper normal value
- • Transaminases \<= 3 x upper normal value \<= 5 x upper normal value in case of liver metastasis
- • Creatinine \<= 1.5mg/dL
- • Patients should be recovered from toxicities of previous treatment.
- • Written informed consent by patient or surrogates
- Exclusion Criteria:
- • Patients who had been previously treated with chemotherapy for NSCLC
- • Active infection requiring antibiotics treatment
- • Prior diagnosis of other malignancy except radically treated basal cell or squamous cell carcinoma of the skin and carcinoma in situ of the uterine cervix
- • Peripheral neuropathy \>= grade 2 by NCI CTCAE 4.0
- • Uncontrolled hypertension, Acute myocardial infarction within 6 months Unstable angina, Congestive heart failure \>= NYHA grade 2 Uncontrolled significant arrhythmia
- • Patients who entered other clinical trials within 4 weeks
- • Pregnant or lactating women. women with child bearing age who are not willing to a contraceptive measure
About Chonnam National University Hospital
Chonnam National University Hospital, a leading medical institution in South Korea, is at the forefront of clinical research and innovation. As a sponsor of clinical trials, the hospital leverages its robust academic resources and multidisciplinary expertise to advance medical knowledge and improve patient care. With a commitment to ethical standards and patient safety, Chonnam National University Hospital collaborates with various stakeholders in the healthcare community to conduct rigorous studies that explore new therapies and treatment modalities. Its state-of-the-art facilities and dedicated research teams contribute to the successful execution of trials across a wide range of medical disciplines.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hwasun, Jeonnam, Korea, Republic Of
Patients applied
Trial Officials
Young-Chul Kim, MD, PhD
Principal Investigator
Chonnam National University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials